Biotech

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Medtronic Is Separating Its Diabetes Business - Good News For Investors

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion

Biotech Recent News

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

CSPC Pharma Pursues Licensing Deals After Lackluster Earnings

Giant Biogene Bruised In A 'Battle Of The Skincare Belles'

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.

Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs

Eli Lilly signed a licensing deal with Juvena for muscle health using its AI-enabled stem-cell protein screening platform.

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

H.C. Wainwright's Brandon Folkes initiated Omeros with a Buy.

Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.